Natera Dirección
Dirección controles de criterios 3/4
El CEO de Natera es Steve Chapman , nombrado en Jan 2019, tiene una permanencia de 7.33 años. compensación anual total es $14.96M, compuesta por 5.7% salario y 94.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.018% de las acciones de la empresa, por valor de $5.26M. La antigüedad media del equipo directivo y de la junta directiva es de 7.3 años y 7.8 años, respectivamente.
Información clave
Steve Chapman
Chief Executive Officer (CEO)
US$15.0m
Compensación total
| Porcentaje del salario del CEO | 5.71% |
| Permanencia del CEO | 7.3yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 7.3yrs |
| Promedio de permanencia en la Junta Directiva | 7.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Artículo de análisis • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...
Actualización de narrativa • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
Actualización de narrativa • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.
Actualización de narrativa • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.Actualización de narrativa • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.Seeking Alpha • Mar 17
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
Summary NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA’s 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA’s MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA’s valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Read the full article on Seeking AlphaActualización de narrativa • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.Actualización de narrativa • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.Actualización de narrativa • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.Actualización de narrativa • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.Actualización de narrativa • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.Actualización de narrativa • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.Actualización de narrativa • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.Actualización de narrativa • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.Actualización de narrativa • Nov 11
NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.Actualización de narrativa • Oct 27
Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets
Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.Actualización de narrativa • Sep 28
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.Actualización de narrativa • Sep 04
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.Artículo de análisis • Aug 31
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Nueva narrativa • May 11
Signatera, Prospera And Renasight Will Transform Diagnostics
Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$226m |
| Dec 31 2025 | US$15m | US$854k | -US$208m |
| Sep 30 2025 | n/a | n/a | -US$309m |
| Jun 30 2025 | n/a | n/a | -US$253m |
| Mar 31 2025 | n/a | n/a | -US$190m |
| Dec 31 2024 | US$13m | US$800k | -US$190m |
| Sep 30 2024 | n/a | n/a | -US$215m |
| Jun 30 2024 | n/a | n/a | -US$292m |
| Mar 31 2024 | n/a | n/a | -US$365m |
| Dec 31 2023 | US$13m | US$751k | -US$435m |
| Sep 30 2023 | n/a | n/a | -US$499m |
| Jun 30 2023 | n/a | n/a | -US$512m |
| Mar 31 2023 | n/a | n/a | -US$546m |
| Dec 31 2022 | US$8m | US$610k | -US$548m |
| Sep 30 2022 | n/a | n/a | -US$546m |
| Jun 30 2022 | n/a | n/a | -US$576m |
| Mar 31 2022 | n/a | n/a | -US$546m |
| Dec 31 2021 | US$23m | US$526k | -US$472m |
| Sep 30 2021 | n/a | n/a | -US$408m |
| Jun 30 2021 | n/a | n/a | -US$315m |
| Mar 31 2021 | n/a | n/a | -US$258m |
| Dec 31 2020 | US$8m | US$487k | -US$230m |
| Sep 30 2020 | n/a | n/a | -US$189m |
| Jun 30 2020 | n/a | n/a | -US$153m |
| Mar 31 2020 | n/a | n/a | -US$126m |
| Dec 31 2019 | US$6m | US$451k | -US$125m |
Compensación vs. Mercado: La compensación total ($USD14.96M) de Steve está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD14.80M).
Compensación vs. Ingresos: La compensación de Steve ha aumentado mientras la empresa no es rentable.
CEO
Steve Chapman (46 yo)
7.3yrs
Permanencia
US$14,957,319
Compensación
Mr. Steven Leonard Chapman, also known as Steve, has been Chief Executive Officer and Director at Natera, Inc. since January 02, 2019. He served as President at Natera, Inc. since January 02, 2019. Mr. Cha...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.3yrs | US$11.28m | 1.61% $ 471.8m | |
| CEO & Director | 7.3yrs | US$14.96m | 0.018% $ 5.3m | |
| President & Chief Business Officer | 2.7yrs | US$5.05m | 0.10% $ 29.8m | |
| Chief Financial Officer | 9.3yrs | US$5.46m | 0.011% $ 3.2m | |
| President of Clinical Diagnostics | no data | US$5.37m | 0.051% $ 14.9m | |
| Co-Founder & Director | no data | US$657.99k | 0.20% $ 58.7m | |
| Chief Accounting Officer | 4.2yrs | sin datos | sin datos | |
| Chief Technology Officer | no data | sin datos | sin datos | |
| Chief Scientific Officer | 6.3yrs | sin datos | sin datos | |
| Secretary & Chief Legal Officer | no data | US$3.33m | 0.13% $ 38.0m | |
| Chief Compliance & Privacy Officer | 8.8yrs | sin datos | sin datos | |
| Chief Sales Officer | 10.2yrs | sin datos | sin datos |
7.3yrs
Permanencia media
46yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de NTRA es experimentado (7.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.3yrs | US$11.28m | 1.61% $ 471.8m | |
| CEO & Director | 7.3yrs | US$14.96m | 0.018% $ 5.3m | |
| Co-Founder & Director | 19.3yrs | US$657.99k | 0.20% $ 58.7m | |
| Independent Director | 9.3yrs | US$501.07k | 0.013% $ 3.8m | |
| Lead Independent Director | 19.3yrs | US$513.46k | 0.81% $ 236.6m | |
| Independent Director | 9.2yrs | US$492.02k | 0.0027% $ 795.3k | |
| Independent Director | 6.8yrs | US$497.16k | 0.0026% $ 774.8k | |
| Independent Director | 7.8yrs | US$427.46k | 0.011% $ 3.4m | |
| Independent Director | 3.2yrs | US$429.17k | 0.0023% $ 683.8k | |
| Independent Director | 1.2yrs | US$468.49k | 0.00092% $ 270.0k | |
| Independent Director | less than a year | sin datos | 0% $ 0 |
7.8yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de NTRA se considera experimentada (7.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 23:01 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Natera, Inc. está cubierta por 30 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |